Novastem Treats Its First Stroke Patient With Stemedica’s Mesenchymal and Neural Stem Cell Combination


The biotech company Novastem is a leader in regenerative medicine and has announced the treatment of its first patient in its clinical study for ischemic stroke at Clinica Santa Clarita, Mexico. This clinical trial is testing cell products made by Stemedica. In particular, Stemedica’s ischemia-tolerant mesenchymal stem cells (itMSCs) were administered in combination with ischemia-tolerant neural stem cells (itNSCs); both of which are proprietary products of Stemedica.

Stemedica‘s itMSCs and itNSCs are unique because of the manner in which they are manufactured – they are grown under conditions that make them resistant to low-oxygen conditions. Experiments conducted with these cells in culture and in living animals have definitely shown that when these cells are exposed to low-oxygen conditions, they show greater homing and engraftment than cells grown under normal conditions. Compared to other MSCs and NSCs, Stemedica’s stem cells secrete higher levels of growth factors and other important proteins associated with angiogenesis and healing.

According to the American Stroke Association, ischemic strokes account for 87 percent of all stroke cases. Novastem is continuing to enroll qualified patients in their study. This clinical trial is entitled “Internal Research Protocol in Combination Therapy of Intravenous Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal Administration of Neural Stem Cells in Patients with Motor Aphasia due to Ischemic Stroke.” All participants in this clinical trial will receive a unique, combination stem cell therapy consisting of cells made by Stemedica Cell Technologies.

Novastem is sponsoring this clinical trial and Novastem is the only company licensed to use Stemedica’s stem cell products for studies in Mexico. Novastem’s Clinica Santa Clarita facility is federally licensed to use stem cell therapies, and this trial marks the first time ischemic stroke is being treated with a patented medical method that comprises administration of hypoxically-grown neural stem cells into the cerebrospinal fluid in combination with intravenous administration of hypoxically-grown mesenchymal stem cells. This combination approach is designed to treat the after effects of ischemic strokes.

“Novastem and Clinica Santa Clarita are committed to advancing the research of neurodegenerative disease, and we are pleased to be working with internationally-recognized physician Clemente Humberto Zuniga Gil, MD as the principal investigator and study designer,” says Rafael Carrillo, Novastem’s President. “Our medical team believes that Stemedica’s mesenchymal and neural stem cells, used in this unique combination therapy, will restore and build new vascularization, improve the blood supply, reconnect damaged neural networks and improve functionality of areas affected by our patients’ ischemic stroke.”

The aim of this Novastem study is to evaluate functional changes on subjects after the administration of ischemia-tolerant mesenchymal and neural stem cells. The protocol in use in this clinical trial has been approved by the Research Ethics Committee of Clinica Santa Clarita, which is federally registered and licensed by the Federal Commission for the Protection against Sanitary Risk (COFEPRIS), a division of Mexico’s Ministry of Health.

Patient progress will be tracked at the beginning of the study before any cells have been administered, at 90 days after stem cell administration, and then again at 180 days after administration. Patient improvement will be ascertained with the United States National Institute of Health Stroke Score (NIHSS), Stroke and Aphasia Quality of Life Scale-39 (SAQCOL-39) and the Boston Diagnostic Aphasia Examination (BDAE) neuropsychological evaluation for diagnosis. Additionally, MRIs taken with a gadolinium-based contrast agent (GBCA) will examine the structural integrity of the brain before and after stem cell administration. At the endpoint, the treatment will be evaluated for safety and tolerance of the two-cell treatment. Additionally, patients will be evaluated for changes in neurological functionality.

Advertisements

Published by

mburatov

Professor of Biochemistry at Spring Arbor University (SAU) in Spring Arbor, MI. Have been at SAU since 1999. Author of The Stem Cell Epistles. Before that I was a postdoctoral research fellow at the University of Pennsylvania in Philadelphia, PA (1997-1999), and Sussex University, Falmer, UK (1994-1997). I studied Cell and Developmental Biology at UC Irvine (PhD 1994), and Microbiology at UC Davis (MA 1986, BS 1984).